Bezafibrate

Bezafibrate

Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a682711
Routes of administration	Oral
ATC code	C10AB02 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Identifiers
IUPAC name 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid
CAS Number	41859-67-0 Y
PubChem CID	39042
IUPHAR/BPS	2668
DrugBank	DB01393 Y
ChemSpider	35728 Y
UNII	Y9449Q51XH
KEGG	D01366 Y
ChEBI	CHEBI:47612 Y
ChEMBL	ChEMBL264374 Y
CompTox Dashboard (EPA)	DTXSID3029869
ECHA InfoCard	100.050.498
Chemical and physical data
Formula	C19H20ClNO4
Molar mass	361.82 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(c1ccc(Cl)cc1)NCCc2ccc(OC(C(=O)O)(C)C)cc2
InChI InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24) Y Key:IIBYAHWJQTYFKB-UHFFFAOYSA-N Y
(verify)

Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL.

It was patented in 1971 and approved for medical use in 1978.^[1]